



# Sponsorers syn på framtidens studier






Focused on R&D in three main therapy areas and across key platforms



Main therapy areas



Opportunity-led



Oncology



Cardiovascular  
and metabolic  
diseases



Respiratory



Autoimmunity,  
neuroscience and  
infection

# Healthcare sector is best placed to benefit from the merging of physical, digital and biological systems, but it is among the least well prepared<sup>1</sup>



1. Power to the patient: How mobile technology is transforming healthcare. The Economist Intelligence Unit Report 2015





Innovative medicines are needed more than ever

Source: WHO



**8 million**  
lives claimed by  
cancer every year



**17 million**  
deaths from  
cardiovascular disease  
every year



**347 million**  
people worldwide  
have diabetes



**235 million**  
people suffer from  
asthma



# Oncology

---

For more than 40 years, we have developed cancer drugs.

Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as cause of death.

---

## Main therapy areas

- > Breast
- > Ovaries
- > Lungs
- > Hematologic

## Specific orientations

- > Tumour drivers and resistance
- > DNA damage response (DDR)
- > Antibody conjugates
- > Immuno-oncology (IO)



# Cardiovascular and Metabolic Diseases

---

Because we know that cardiovascular diseases are a well-known consequence of diabetes and chronic kidney disease, we take an integrated patient-centric approach. We seek to reduce cardiovascular morbidity and mortality, and organ damage by addressing multiple cardiovascular risk factors.

---

## Cardiovascular and Metabolic Diseases

### Focus on medicines for:

- > Thrombosis
- > Atherosclerosis
- > Dyslipidaemia
- > Hypertension
- > Heart failure
- > Diabetes
- > Chronic kidney disease (CKD)



# Respiratory diseases

---

**Our goal is to establish a leading position in asthma and COPD treatment, by delivering a range of differentiated inhaled therapies, novel combinations and devices, and biologics.**

---

## Respiratory

Working to transform disease management and patient outcomes in:

- > Asthma
- > COPD

Our research will potentially result in the first treatment of:

- > Idiopathic pulmonary fibrosis (IPF)

# The future of Clinical Drug Development

Increased participation through reduced burden  
(both patients and investigators)

Reduce cost and time while quality is non-negotiable

Technology and access will enable and force transformation



**Digital 4.0 (digitalization, mobilization & patient power) will be disruptive and lead into a world of integrated/unified solutions**

